Carrie Elizabeth Cunningham, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 46 | 2022 | 2360 | 4.740 |
Why?
|
Thyroidectomy | 20 | 2021 | 915 | 3.030 |
Why?
|
Thyroid Nodule | 14 | 2022 | 766 | 1.990 |
Why?
|
Hyperparathyroidism, Primary | 6 | 2021 | 164 | 1.740 |
Why?
|
Adenocarcinoma, Follicular | 6 | 2021 | 325 | 1.540 |
Why?
|
Thyroid Diseases | 3 | 2020 | 388 | 1.340 |
Why?
|
Carcinoma, Papillary | 11 | 2018 | 792 | 1.310 |
Why?
|
Endocrinology | 4 | 2021 | 443 | 1.130 |
Why?
|
Proto-Oncogene Proteins B-raf | 9 | 2021 | 2072 | 1.050 |
Why?
|
Parathyroidectomy | 4 | 2019 | 244 | 0.960 |
Why?
|
Iodine Radioisotopes | 4 | 2021 | 1035 | 0.820 |
Why?
|
Adrenalectomy | 6 | 2022 | 348 | 0.800 |
Why?
|
Four-Dimensional Computed Tomography | 3 | 2021 | 142 | 0.700 |
Why?
|
Endocrine System Diseases | 1 | 2022 | 250 | 0.690 |
Why?
|
Thyroid Gland | 6 | 2020 | 1172 | 0.620 |
Why?
|
Biopsy, Fine-Needle | 12 | 2022 | 1131 | 0.600 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2021 | 342 | 0.590 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3708 | 0.590 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2022 | 736 | 0.550 |
Why?
|
Technetium Tc 99m Sestamibi | 3 | 2021 | 184 | 0.530 |
Why?
|
Parathyroid Neoplasms | 3 | 2016 | 244 | 0.500 |
Why?
|
Carcinoma | 4 | 2017 | 2341 | 0.460 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2020 | 9425 | 0.420 |
Why?
|
Adenoma | 5 | 2016 | 2163 | 0.410 |
Why?
|
Hypoparathyroidism | 1 | 2014 | 136 | 0.410 |
Why?
|
Hematoma | 3 | 2019 | 768 | 0.400 |
Why?
|
Endocrine Surgical Procedures | 1 | 2021 | 32 | 0.370 |
Why?
|
Parathyroid Glands | 2 | 2021 | 522 | 0.370 |
Why?
|
Mutation | 10 | 2021 | 30243 | 0.360 |
Why?
|
Oxyphil Cells | 1 | 2020 | 56 | 0.340 |
Why?
|
Parathyroid Diseases | 1 | 2019 | 46 | 0.340 |
Why?
|
Adenoma, Oxyphilic | 1 | 2021 | 152 | 0.330 |
Why?
|
Gastric Bypass | 2 | 2015 | 829 | 0.330 |
Why?
|
Oncogene Fusion | 2 | 2021 | 83 | 0.320 |
Why?
|
Financing, Personal | 1 | 2021 | 310 | 0.320 |
Why?
|
Gene Expression Profiling | 7 | 2015 | 9507 | 0.320 |
Why?
|
Hyperthyroidism | 2 | 2021 | 295 | 0.310 |
Why?
|
Health Care Costs | 5 | 2016 | 3265 | 0.300 |
Why?
|
Graves Disease | 2 | 2013 | 239 | 0.290 |
Why?
|
Parathyroid Hormone | 4 | 2016 | 1804 | 0.280 |
Why?
|
Practice Guidelines as Topic | 5 | 2021 | 7451 | 0.280 |
Why?
|
Radiotherapy | 3 | 2021 | 1510 | 0.270 |
Why?
|
Postoperative Complications | 7 | 2020 | 15880 | 0.260 |
Why?
|
Humans | 78 | 2022 | 768451 | 0.260 |
Why?
|
Quality of Life | 8 | 2021 | 13497 | 0.260 |
Why?
|
Radiopharmaceuticals | 2 | 2021 | 2731 | 0.250 |
Why?
|
Carcinoma, Papillary, Follicular | 2 | 2014 | 59 | 0.250 |
Why?
|
Career Choice | 1 | 2021 | 769 | 0.240 |
Why?
|
Middle Aged | 38 | 2022 | 223418 | 0.240 |
Why?
|
Malpractice | 1 | 2019 | 561 | 0.240 |
Why?
|
Hyperparathyroidism | 1 | 2016 | 339 | 0.230 |
Why?
|
Adrenal Gland Diseases | 1 | 2015 | 141 | 0.230 |
Why?
|
Tissue and Organ Harvesting | 1 | 2017 | 374 | 0.230 |
Why?
|
Obesity, Morbid | 1 | 2015 | 1309 | 0.220 |
Why?
|
Blood Chemical Analysis | 1 | 2015 | 436 | 0.220 |
Why?
|
Neck Dissection | 2 | 2017 | 201 | 0.220 |
Why?
|
Ultrasonography | 7 | 2021 | 5995 | 0.210 |
Why?
|
Calcium | 4 | 2019 | 5793 | 0.210 |
Why?
|
Living Donors | 1 | 2017 | 651 | 0.210 |
Why?
|
Calcitonin | 2 | 2011 | 329 | 0.200 |
Why?
|
Hyperaldosteronism | 1 | 2015 | 250 | 0.200 |
Why?
|
Otolaryngology | 1 | 2019 | 698 | 0.200 |
Why?
|
Survival Rate | 8 | 2022 | 12875 | 0.200 |
Why?
|
Models, Economic | 2 | 2015 | 717 | 0.200 |
Why?
|
Female | 43 | 2022 | 396943 | 0.190 |
Why?
|
Adult | 30 | 2021 | 223542 | 0.190 |
Why?
|
Retrospective Studies | 22 | 2022 | 81834 | 0.190 |
Why?
|
Pheochromocytoma | 1 | 2014 | 328 | 0.190 |
Why?
|
Postoperative Care | 1 | 2018 | 1481 | 0.190 |
Why?
|
United States | 16 | 2021 | 73121 | 0.190 |
Why?
|
Cost-Benefit Analysis | 3 | 2020 | 5532 | 0.180 |
Why?
|
Patient Selection | 3 | 2017 | 4266 | 0.180 |
Why?
|
Male | 38 | 2022 | 364781 | 0.180 |
Why?
|
Decision Trees | 1 | 2012 | 510 | 0.180 |
Why?
|
Cytodiagnosis | 3 | 2020 | 452 | 0.180 |
Why?
|
Transcription Factor CHOP | 1 | 2010 | 69 | 0.170 |
Why?
|
Convalescence | 1 | 2020 | 109 | 0.170 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2834 | 0.170 |
Why?
|
Cost of Illness | 1 | 2019 | 1960 | 0.170 |
Why?
|
Drug Resistance | 1 | 2015 | 1599 | 0.170 |
Why?
|
Aged | 25 | 2021 | 171520 | 0.160 |
Why?
|
Drainage | 2 | 2013 | 1179 | 0.150 |
Why?
|
General Surgery | 1 | 2019 | 1714 | 0.150 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3543 | 0.150 |
Why?
|
Neoplasm Staging | 4 | 2021 | 11249 | 0.150 |
Why?
|
Health Status | 2 | 2020 | 4096 | 0.140 |
Why?
|
Neoplasm Invasiveness | 3 | 2018 | 3637 | 0.140 |
Why?
|
Reoperation | 4 | 2021 | 4342 | 0.140 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13589 | 0.140 |
Why?
|
Insurance, Health | 2 | 2021 | 2513 | 0.140 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 1937 | 0.140 |
Why?
|
Physical Exertion | 1 | 2020 | 669 | 0.140 |
Why?
|
Selenium | 1 | 2010 | 419 | 0.140 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 920 | 0.140 |
Why?
|
Sarcoma | 1 | 2018 | 1806 | 0.140 |
Why?
|
Preoperative Care | 2 | 2013 | 2257 | 0.140 |
Why?
|
Antihypertensive Agents | 1 | 2015 | 2028 | 0.130 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2021 | 470 | 0.130 |
Why?
|
Decision Support Techniques | 1 | 2015 | 2010 | 0.120 |
Why?
|
Ultrasonography, Interventional | 1 | 2013 | 1519 | 0.120 |
Why?
|
Models, Theoretical | 1 | 2017 | 3590 | 0.120 |
Why?
|
Postoperative Period | 2 | 2020 | 1833 | 0.120 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2015 | 125 | 0.110 |
Why?
|
Quality Improvement | 1 | 2019 | 3858 | 0.110 |
Why?
|
Pancreaticoduodenectomy | 1 | 2017 | 516 | 0.110 |
Why?
|
Disease-Free Survival | 3 | 2022 | 6856 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5426 | 0.110 |
Why?
|
DNA, Mitochondrial | 1 | 2018 | 871 | 0.100 |
Why?
|
DNA Mutational Analysis | 2 | 2016 | 4120 | 0.100 |
Why?
|
Survivors | 2 | 2017 | 2381 | 0.100 |
Why?
|
Cell Division | 1 | 2010 | 4479 | 0.100 |
Why?
|
Hypocalcemia | 1 | 2013 | 203 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1781 | 0.100 |
Why?
|
Prognosis | 7 | 2018 | 30028 | 0.100 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 1734 | 0.090 |
Why?
|
Microarray Analysis | 2 | 2010 | 752 | 0.090 |
Why?
|
Watchful Waiting | 2 | 2016 | 496 | 0.090 |
Why?
|
Guideline Adherence | 1 | 2021 | 2239 | 0.090 |
Why?
|
Phosphotransferases | 1 | 2021 | 303 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20762 | 0.080 |
Why?
|
Blood Pressure | 1 | 2015 | 8538 | 0.080 |
Why?
|
Cell Nucleus | 1 | 2018 | 2889 | 0.080 |
Why?
|
SEER Program | 2 | 2021 | 1476 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 4586 | 0.080 |
Why?
|
Aged, 80 and over | 8 | 2020 | 59680 | 0.080 |
Why?
|
Pathology, Molecular | 1 | 2022 | 329 | 0.080 |
Why?
|
Cohort Studies | 6 | 2020 | 41797 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 5 | 2009 | 3794 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2021 | 1794 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 18048 | 0.080 |
Why?
|
Neck | 1 | 2013 | 736 | 0.080 |
Why?
|
Netherlands | 1 | 2013 | 2274 | 0.080 |
Why?
|
Genotype | 3 | 2016 | 13047 | 0.080 |
Why?
|
Tumor Burden | 2 | 2018 | 1909 | 0.080 |
Why?
|
Hypertension | 2 | 2015 | 8611 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2010 | 3463 | 0.080 |
Why?
|
Geographic Information Systems | 1 | 2020 | 283 | 0.080 |
Why?
|
Radionuclide Imaging | 1 | 2012 | 1998 | 0.070 |
Why?
|
Canada | 1 | 2013 | 2143 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39430 | 0.070 |
Why?
|
Pandemics | 2 | 2022 | 8753 | 0.070 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2022 | 614 | 0.070 |
Why?
|
Disease Progression | 2 | 2022 | 13655 | 0.070 |
Why?
|
Adolescent | 7 | 2021 | 89168 | 0.070 |
Why?
|
Time Factors | 5 | 2020 | 40271 | 0.070 |
Why?
|
Gene Expression | 1 | 2010 | 7605 | 0.070 |
Why?
|
Prospective Studies | 6 | 2021 | 54914 | 0.070 |
Why?
|
Hypercalcemia | 1 | 2019 | 423 | 0.070 |
Why?
|
Markov Chains | 1 | 2020 | 977 | 0.070 |
Why?
|
Splenic Neoplasms | 1 | 2006 | 97 | 0.060 |
Why?
|
Hemangioma, Capillary | 1 | 2006 | 64 | 0.060 |
Why?
|
Risk Assessment | 4 | 2017 | 24311 | 0.060 |
Why?
|
Treatment Outcome | 6 | 2020 | 65409 | 0.060 |
Why?
|
Psychometrics | 2 | 2020 | 3072 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12096 | 0.060 |
Why?
|
Intraoperative Period | 1 | 2016 | 513 | 0.060 |
Why?
|
Lymphatic Metastasis | 2 | 2012 | 2930 | 0.060 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2925 | 0.060 |
Why?
|
Vitamin D | 2 | 2015 | 3311 | 0.060 |
Why?
|
Methimazole | 1 | 2013 | 41 | 0.060 |
Why?
|
Propylthiouracil | 1 | 2013 | 68 | 0.060 |
Why?
|
Antithyroid Agents | 1 | 2013 | 72 | 0.050 |
Why?
|
Young Adult | 5 | 2021 | 60045 | 0.050 |
Why?
|
Laparotomy | 1 | 2015 | 459 | 0.050 |
Why?
|
Employment | 1 | 2019 | 1120 | 0.050 |
Why?
|
Life Expectancy | 1 | 2020 | 1249 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 2020 | 21156 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11843 | 0.050 |
Why?
|
Massachusetts | 2 | 2017 | 8908 | 0.050 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1884 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2014 | 228 | 0.050 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2011 | 40 | 0.050 |
Why?
|
Mastectomy | 1 | 2020 | 1852 | 0.050 |
Why?
|
Telomerase | 2 | 2018 | 751 | 0.050 |
Why?
|
Tachycardia | 1 | 2014 | 599 | 0.050 |
Why?
|
Carcinoma, Medullary | 1 | 2011 | 116 | 0.050 |
Why?
|
Neoplasms | 2 | 2020 | 22386 | 0.050 |
Why?
|
Program Evaluation | 1 | 2019 | 2508 | 0.050 |
Why?
|
Hypotension, Orthostatic | 1 | 2014 | 258 | 0.040 |
Why?
|
Ablation Techniques | 1 | 2013 | 249 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2013 | 22293 | 0.040 |
Why?
|
Risk Factors | 4 | 2021 | 74915 | 0.040 |
Why?
|
Carcinoembryonic Antigen | 1 | 2011 | 338 | 0.040 |
Why?
|
Incidence | 3 | 2016 | 21552 | 0.040 |
Why?
|
Cell Nucleus Size | 1 | 2010 | 10 | 0.040 |
Why?
|
Cell Nucleus Shape | 1 | 2010 | 16 | 0.040 |
Why?
|
Selenomethionine | 1 | 2010 | 18 | 0.040 |
Why?
|
Patient Care | 1 | 2016 | 629 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2014 | 738 | 0.040 |
Why?
|
Seroma | 1 | 2010 | 74 | 0.040 |
Why?
|
Cluster Analysis | 3 | 2009 | 2731 | 0.040 |
Why?
|
Protein Phosphatase 1 | 1 | 2010 | 135 | 0.040 |
Why?
|
Treatment Failure | 1 | 2015 | 2656 | 0.040 |
Why?
|
Cell Nucleolus | 1 | 2010 | 156 | 0.040 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2011 | 249 | 0.040 |
Why?
|
Gene Rearrangement | 1 | 2014 | 1139 | 0.040 |
Why?
|
In Situ Nick-End Labeling | 1 | 2010 | 616 | 0.040 |
Why?
|
Cell Shape | 1 | 2010 | 371 | 0.040 |
Why?
|
Thyrotropin | 1 | 2012 | 834 | 0.040 |
Why?
|
Incidental Findings | 1 | 2013 | 699 | 0.040 |
Why?
|
Haploidy | 1 | 2018 | 127 | 0.040 |
Why?
|
Preoperative Period | 1 | 2010 | 564 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2015 | 1734 | 0.040 |
Why?
|
Length of Stay | 2 | 2013 | 6521 | 0.040 |
Why?
|
Cell Size | 1 | 2010 | 626 | 0.040 |
Why?
|
Lymphocytes | 1 | 2015 | 2611 | 0.040 |
Why?
|
Antacids | 1 | 2017 | 94 | 0.040 |
Why?
|
Drug Costs | 1 | 2015 | 1196 | 0.040 |
Why?
|
Enzyme Replacement Therapy | 1 | 2017 | 80 | 0.040 |
Why?
|
Mortality | 1 | 2018 | 2917 | 0.040 |
Why?
|
Pilot Projects | 1 | 2020 | 8730 | 0.030 |
Why?
|
Anemia | 1 | 2006 | 1521 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15460 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3438 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2017 | 1946 | 0.030 |
Why?
|
Cell Count | 1 | 2010 | 1835 | 0.030 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 1142 | 0.030 |
Why?
|
Immunotherapy | 1 | 2021 | 4728 | 0.030 |
Why?
|
Pancreatic Diseases | 1 | 2017 | 353 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2016 | 3472 | 0.030 |
Why?
|
Functional Laterality | 1 | 2010 | 2268 | 0.030 |
Why?
|
Databases, Factual | 1 | 2019 | 8081 | 0.030 |
Why?
|
Laparoscopy | 1 | 2015 | 2056 | 0.030 |
Why?
|
Exercise | 2 | 2020 | 5940 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2010 | 2362 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2016 | 2775 | 0.030 |
Why?
|
Registries | 1 | 2019 | 8373 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3550 | 0.030 |
Why?
|
Galectin 3 | 1 | 2005 | 240 | 0.030 |
Why?
|
Blotting, Western | 1 | 2010 | 5042 | 0.020 |
Why?
|
Computer Simulation | 1 | 2015 | 6278 | 0.020 |
Why?
|
PPAR gamma | 1 | 2005 | 487 | 0.020 |
Why?
|
Anxiety | 1 | 2016 | 4655 | 0.020 |
Why?
|
Linear Models | 1 | 2011 | 5880 | 0.020 |
Why?
|
Cell Cycle | 1 | 2010 | 2942 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2005 | 568 | 0.020 |
Why?
|
Cadherins | 1 | 2005 | 906 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2005 | 1246 | 0.020 |
Why?
|
DNA Damage | 1 | 2010 | 2461 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2046 | 0.020 |
Why?
|
ras Proteins | 1 | 2005 | 1058 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2994 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2010 | 2643 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2010 | 5904 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2005 | 1119 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18388 | 0.020 |
Why?
|
Sex Factors | 1 | 2012 | 10647 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4931 | 0.020 |
Why?
|
Contrast Media | 1 | 2010 | 5336 | 0.020 |
Why?
|
Logistic Models | 1 | 2011 | 13324 | 0.020 |
Why?
|
Depression | 1 | 2016 | 8235 | 0.020 |
Why?
|
Phenotype | 1 | 2014 | 16712 | 0.020 |
Why?
|
Age Factors | 1 | 2012 | 18478 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2010 | 12813 | 0.010 |
Why?
|
Splenectomy | 1 | 2006 | 392 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 13026 | 0.010 |
Why?
|
Apoptosis | 1 | 2010 | 9526 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7863 | 0.010 |
Why?
|
Obesity | 1 | 2015 | 13065 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2010 | 17149 | 0.010 |
Why?
|
Child | 2 | 2011 | 80863 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2391 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2005 | 11138 | 0.010 |
Why?
|
Mice | 1 | 2018 | 82045 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2006 | 8635 | 0.010 |
Why?
|
Spleen | 1 | 2006 | 2298 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2017 | 5442 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2005 | 19041 | 0.010 |
Why?
|
Heart Failure | 1 | 2014 | 11857 | 0.010 |
Why?
|
Child, Preschool | 1 | 2011 | 42623 | 0.010 |
Why?
|
Prevalence | 1 | 2014 | 15880 | 0.010 |
Why?
|
Animals | 1 | 2018 | 169418 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14728 | 0.010 |
Why?
|